I saw remdesivir got EUA for mild-moderate. Leronlimab's data is better but being phase 2, the FDA will probably require a phase 3.
Hopefully the severe interim phase 3 analysis is great.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
-
-
-
-
-
-
-